QIAGEN’s QuantiFERON Test Cuts HIV TB Progression Risk by 41%, Expands AI and Automation
QIAGEN data show QuantiFERON-TB Gold Plus test cut lifetime risk of active TB by 41% versus the tuberculin skin test in HIV patients and lowered costs. QIAGEN is developing a fifth-generation QuantiFERON assay, exploring AI-driven risk prediction and scaling automation via a Diasorin partnership to boost TB testing capacity.
1. Published Clinical and Economic Findings
A BMC Public Health study in Thailand showed QIAGEN’s QuantiFERON-TB Gold Plus test reduced modeled lifetime progression to active TB by 41% versus the tuberculin skin test in HIV patients, while lowering lifetime healthcare costs. These findings reinforce the assay’s value in immunocompromised and high-risk populations, potentially driving broader clinical adoption.
2. Market Footprint and Usage
Over 2,500 peer-reviewed studies have validated QuantiFERON performance, with more than 125 million tests administered globally. The assay’s demonstrated accuracy in diverse patient groups underpins its leading role in TB infection detection and prevention strategies.
3. Pipeline: Fifth-Generation Assay and AI
QIAGEN is advancing development of a fifth-generation QuantiFERON assay aimed at enhancing sensitivity and workflow efficiency. Early research into AI-driven models combining test results with clinical factors seeks to improve risk prediction for latent TB progression and guide targeted preventive treatment.
4. Automation Scale-Up Partnership
A collaboration with Diasorin will enable QuantiFERON testing on LIAISON automated immunodiagnostic systems, supporting scalable, high-throughput TB infection screening. This partnership is designed to streamline laboratory workflows and meet rising global demand for rapid, reliable TB diagnostics.